Last update Jan. 21, 2021
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Φλουνιτραζεπάμη is Flunitrazepam in Greek.Is written in other languages:
Φλουνιτραζεπάμη belongs to this group or family:
Main tradenames from several countries containing Φλουνιτραζεπάμη in its composition:
|Oral Bioavail.||64 - 77||%|
|T½||18 - 26||hours|
|M/P ratio||0.5 - 0.9||-|
|Theoretical Dose||0.0004 - 0.0006||mg/Kg/d|
|Relative Dose||1 - 2.5||%|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It si an intermediate- or short-acting benzodiazepine indicated in the management of insomnia, as a premedicant in surgical procedures, and for induction of anaesthesia
Oral, intramuscularly or intravenous administration once a day.
It is excreted in breast milk in clinically insignificant amounts (Nishimura 2021, Kanto 1979) and no problems have been observed in infants whose mothers have taken it (Nishimura 2021).
The occasional use and low doses of benzodiazepines are compatible with breastfeeding (Kelly 2012, Rubin 2004, Iqbal 2002, Hägg 2000, McElhatton 1994, Lee 1993, Kanto 1982).
It is advisable to choose a short-acting benzodiazepine and minimal effective dose as possible (Rowe 2013), especially in the neonatal period and in case of prematurity because they can accumulate in the infant during chronic use (Sachs 2013, Amir 2011).
It is advisable to monitor drowsiness and adequate feeding of the infant.
It is not recommended to share a bed (co-sleeping, bed-sharing) with the baby if this drug is being taken, due to increased risk of asphyxia or sudden infant death (UNICEF UK 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF UK 2006).